CA3016830C - Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof - Google Patents
Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof Download PDFInfo
- Publication number
- CA3016830C CA3016830C CA3016830A CA3016830A CA3016830C CA 3016830 C CA3016830 C CA 3016830C CA 3016830 A CA3016830 A CA 3016830A CA 3016830 A CA3016830 A CA 3016830A CA 3016830 C CA3016830 C CA 3016830C
- Authority
- CA
- Canada
- Prior art keywords
- crystalline forms
- mesylate salt
- applications
- preparation methods
- pyrimidine derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title abstract 3
- RHXVSZXHWDQESH-UHFFFAOYSA-N 4-pyridin-2-ylpyrimidin-2-amine Chemical class NC1=NC=CC(C=2N=CC=CC=2)=N1 RHXVSZXHWDQESH-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical class FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610127022.3 | 2016-03-07 | ||
| CN201610127022.3A CN107163027B (zh) | 2016-03-07 | 2016-03-07 | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 |
| PCT/CN2017/000203 WO2017152707A1 (zh) | 2016-03-07 | 2017-03-01 | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3016830A1 CA3016830A1 (en) | 2017-09-14 |
| CA3016830C true CA3016830C (en) | 2021-05-18 |
Family
ID=59788981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3016830A Active CA3016830C (en) | 2016-03-07 | 2017-03-01 | Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10550101B2 (zh) |
| EP (1) | EP3428159B1 (zh) |
| JP (1) | JP6894917B2 (zh) |
| KR (1) | KR102142797B1 (zh) |
| CN (2) | CN107163027B (zh) |
| CA (1) | CA3016830C (zh) |
| ES (1) | ES2863923T3 (zh) |
| PL (1) | PL3428159T3 (zh) |
| WO (1) | WO2017152707A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105315259B (zh) | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| CN107163026B (zh) | 2016-03-07 | 2019-07-02 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 |
| CN110606841A (zh) * | 2018-06-15 | 2019-12-24 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的晶型及其制备方法 |
| WO2020233669A1 (zh) * | 2019-05-22 | 2020-11-26 | 上海翰森生物医药科技有限公司 | 含吲哚类衍生物抑制剂、其制备方法和应用 |
| WO2023035223A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海艾力斯医药科技股份有限公司 | 药物组合物及其用途 |
| US12084450B2 (en) * | 2022-06-27 | 2024-09-10 | Abion Inc. | Mesylate salts of triazolopyrazine derivatives |
| CN116478138A (zh) * | 2023-04-21 | 2023-07-25 | 江苏艾力斯生物医药有限公司 | 一种甲磺酸伏美替尼原料药的结晶方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2900230T3 (es) * | 2011-07-27 | 2022-03-16 | Astrazeneca Ab | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina |
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| CN105315259B (zh) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| CN107163026B (zh) | 2016-03-07 | 2019-07-02 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 |
-
2016
- 2016-03-07 CN CN201610127022.3A patent/CN107163027B/zh active Active
- 2016-03-07 CN CN201911024029.2A patent/CN110590749B/zh active Active
-
2017
- 2017-03-01 ES ES17762393T patent/ES2863923T3/es active Active
- 2017-03-01 KR KR1020187028799A patent/KR102142797B1/ko active IP Right Grant
- 2017-03-01 JP JP2018547272A patent/JP6894917B2/ja active Active
- 2017-03-01 WO PCT/CN2017/000203 patent/WO2017152707A1/zh active Application Filing
- 2017-03-01 CA CA3016830A patent/CA3016830C/en active Active
- 2017-03-01 PL PL17762393T patent/PL3428159T3/pl unknown
- 2017-03-01 EP EP17762393.1A patent/EP3428159B1/en active Active
- 2017-03-01 US US16/083,210 patent/US10550101B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3428159T3 (pl) | 2021-08-02 |
| CN107163027A (zh) | 2017-09-15 |
| CN107163027B (zh) | 2019-11-05 |
| US20190092753A1 (en) | 2019-03-28 |
| CN110590749B (zh) | 2020-11-06 |
| JP2019507776A (ja) | 2019-03-22 |
| EP3428159B1 (en) | 2021-01-27 |
| EP3428159A4 (en) | 2019-08-07 |
| US10550101B2 (en) | 2020-02-04 |
| ES2863923T3 (es) | 2021-10-13 |
| CN110590749A (zh) | 2019-12-20 |
| KR20180114227A (ko) | 2018-10-17 |
| EP3428159A1 (en) | 2019-01-16 |
| KR102142797B1 (ko) | 2020-08-10 |
| CA3016830A1 (en) | 2017-09-14 |
| JP6894917B2 (ja) | 2021-06-30 |
| WO2017152707A1 (zh) | 2017-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3016830C (en) | Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| PH12018550120A1 (en) | Steroid derivative fxr agonist | |
| CA3057882A1 (en) | Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein | |
| MX2020003458A (es) | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. | |
| EP4292650A3 (en) | Heterocyclic compounds as immunomodulators | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| EP3587422A4 (en) | PYRROLO-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE-RELATED DISEASE | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| CN106536480A8 (zh) | 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| WO2016028391A3 (en) | Spiropyrrolidines as mdm2 inhibitors | |
| EA201892436A1 (ru) | Пиримидиновые соединения в качестве ингибиторов jak киназы | |
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| CY1111203T1 (el) | 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r | |
| WO2018023072A3 (en) | Compounds and compositions and uses thereof | |
| EP3539951A4 (en) | NOVEL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER AND INFLAMMATORY DISEASES | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| MX2017012295A (es) | Derivados formilados n-heterociclicos como inhibidores de fgfr4. | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| WO2016199076A3 (en) | Polymorphic forms of afatinib free base and afatinib dimaleate | |
| EA201492029A1 (ru) | N-этил-4-гидроксил-1-метил-5-(метил(2,3,4,5,6-пентагидроксигексил)амино)-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| MX2018012777A (es) | Métodos para preparación de ácido obeticólico y derivados de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190704 |